Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.
Ontology highlight
ABSTRACT: The remarkable progress in engineering and clinical development of therapeutic antibodies in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by the United States Food and Drug Administration (FDA) of 21 antibodies for cancer immunotherapy. We review here these approved antibodies, with emphasis on the methods used for their discovery, engineering, and optimization for therapeutic settings. These methods include antibody engineering via chimerization and humanization of non-human antibodies, as well as selection and further optimization of fully human antibodies isolated from human antibody phage-displayed libraries and immunization of transgenic mice capable of generating human antibodies. These technology platforms have progressively led to
SUBMITTER: Almagro JC
PROVIDER: S-EPMC5770808 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA